Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: TAK-875

First Posted Date: 2009-07-30

Last Posted Date: 2010-06-11

Lead Sponsor: Takeda

Target Recruit Count: 60

Registration Number: NCT00949091

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Clopidogrel
Drug: Clopidogrel and Esomeprazole
Drug: Clopidogrel and Dexlansoprazole
Drug: Clopidogrel and Lansoprazole
Drug: Clopidogrel and Omeprazole

First Posted Date: 2009-07-20

Last Posted Date: 2012-02-03

Lead Sponsor: Takeda

Target Recruit Count: 160

Registration Number: NCT00942175

Pharmacokinetic and Safety of Ramelteon Between Adolescents With Insomnia and Healthy Adults

Phase 1

Completed

Conditions: Insomnia

Interventions: Drug: Ramelteon

First Posted Date: 2009-06-05

Last Posted Date: 2012-04-04

Lead Sponsor: Takeda

Target Recruit Count: 56

Registration Number: NCT00914862

Efficacy and Safety of Ramelteon on Chronic Insomnia

Phase 2

Completed

Conditions: Chronic Insomnia

Interventions: Drug: Ramelteon and Placebo (25 possible combinations total)

First Posted Date: 2009-06-05

Last Posted Date: 2010-06-02

Lead Sponsor: Takeda

Target Recruit Count: 66

Registration Number: NCT00915135

Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate

Completed

Conditions: Toxicity

Interventions: Other: Pharmacogenomic whole blood sampling

First Posted Date: 2009-04-29

Last Posted Date: 2012-05-24

Lead Sponsor: Takeda

Target Recruit Count: 66

Registration Number: NCT00890448

Safety of Lapaquistat Acetate in Subjects With Hypercholesterolemia

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Lapaquistat acetate and additional lipid-lowering therapy
Drug: Lapaquistat acetate

First Posted Date: 2009-03-24

Last Posted Date: 2012-05-24

Lead Sponsor: Takeda

Target Recruit Count: 574

Registration Number: NCT00868127

Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in Subjects With Hypercholesterolemia

Phase 2

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Lapaquistat acetate and atorvastatin
Drug: Atorvastatin

First Posted Date: 2009-03-19

Last Posted Date: 2012-05-24

Lead Sponsor: Takeda

Target Recruit Count: 172

Registration Number: NCT00864643

Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia

Phase 2

Terminated

Conditions: Hypercholesterolemia

Interventions: Drug: Lapaquistat acetate
Drug: Placebo

First Posted Date: 2009-03-19

Last Posted Date: 2012-05-24

Lead Sponsor: Takeda

Target Recruit Count: 224

Registration Number: NCT00865228

Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Alogliptin
Drug: Metformin
Drug: Glipizide

First Posted Date: 2009-03-05

Last Posted Date: 2013-12-03

Lead Sponsor: Takeda

Target Recruit Count: 2639

Registration Number: NCT00856284

Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy

Phase 3

Completed

Conditions: Gastroesophageal Reflux

Interventions: Drug: Dexlansoprazole MR QD

First Posted Date: 2009-02-19

Last Posted Date: 2012-02-03

Lead Sponsor: Takeda

Target Recruit Count: 178

Registration Number: NCT00847808

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy